Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.

NPJ breast cancer·2026
Same author

Development and Validation of an Algorithm to Achieve Complete Registration of Danish Patients with Carcinoma In Situ of the Breast, 2008-2023.

Clinical epidemiology·2026
Same author

Statin use and risk of contralateral breast cancer: an updated cohort study with landmark analysis.

European journal of epidemiology·2026
Same author

Metabolic, enterohepatic and gut microbial effects of atorvastatin in healthy men.

Endocrine connections·2026
Same author

17β-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark.

Breast cancer research : BCR·2025
Same author

Validation of a deep learning-based AI model for breast cancer risk stratification in postmenopausal ER+/HER2-breast cancer patients.

Breast (Edinburgh, Scotland)·2025

Related Experiment Video

Updated: Sep 9, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

Enhancing HER2-low breast cancer detection with quantitative transcriptomics.

Maria-Anna Misiakou1, Maj-Britt Jensen2, Maj-Lis Talman3

  • 1Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

NPJ Breast Cancer
|September 1, 2025
PubMed
Summary
This summary is machine-generated.

Transcriptomics accurately identifies HER2 expression in breast cancer, even in cases negative by standard IHC. This method aids in selecting patients for HER2-targeted therapies, improving treatment outcomes.

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Evaluation of Lung Metastasis in Mouse Mammary Tumor Models by Quantitative Real-time PCR
08:56

Evaluation of Lung Metastasis in Mouse Mammary Tumor Models by Quantitative Real-time PCR

Published on: January 29, 2016

10.0K

Related Experiment Videos

Last Updated: Sep 9, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Evaluation of Lung Metastasis in Mouse Mammary Tumor Models by Quantitative Real-time PCR
08:56

Evaluation of Lung Metastasis in Mouse Mammary Tumor Models by Quantitative Real-time PCR

Published on: January 29, 2016

10.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Accurate human epidermal growth factor receptor 2 (HER2) assessment is crucial for breast cancer treatment decisions.
  • Standard immunohistochemistry (IHC) methods struggle to reliably identify HER2-low expression, a growing area of therapeutic interest.

Purpose of the Study:

  • To evaluate the utility of transcriptomics for sensitive detection of ERBB2 (HER2) mRNA expression in breast cancer.
  • To determine if transcriptomic HER2 detection can improve patient stratification for anti-HER2 therapies beyond conventional IHC classification.

Main Methods:

  • Transcriptomic analysis of ERBB2 mRNA expression was performed on a cohort of 3182 breast tumors.
  • Correlation of transcriptomic data with IHC classifications and pathological complete response rates in patients treated with anti-HER2 therapies.

Main Results:

  • Detectable ERBB2 mRNA was identified in 86% of tumors classified as IHC 0 (HER2-negative).
  • Higher ERBB2 mRNA expression levels correlated with increased pathological complete response rates in patients receiving anti-HER2 therapy.

Conclusions:

  • Transcriptomics offers a sensitive method for detecting HER2 expression, complementing standard IHC in breast cancer.
  • This approach can refine patient stratification for HER2-targeted treatments, potentially optimizing therapeutic efficacy.